Sarepta director Stephen Mayo proposes $123K sale

Accepted by SEC EDGAR 03/12/2026 - 04:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. director Stephen Mayo reported a proposed sale of 7,239 common shares, with an aggregate market value of $123,175.20 and an approximate sale date of March 12, 2026. The notice lists 104,989,772 common shares outstanding. The shares were acquired from the issuer as restricted stock in six listed lots dated from November 16, 2022, through March 10, 2026.

Key Figures

Common shares reported for sale: 7,239 shares Aggregate market value: $123,175.20 Common shares outstanding: 104,989,772 shares

3 metrics

Common shares reported for sale 7,239 shares Approximate sale date: March 12, 2026

Aggregate market value $123,175.20 For the common shares reported for sale

Common shares outstanding 104,989,772 shares As reported in the notice

Key Terms

Restricted Stock, Aggregate Market Value, Number of Shares or Other Units Outstanding

3 terms

Restricted Stock financial

"Nature of Acquisition Transaction: Restricted Stock"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Aggregate Market Value financial

"Number of Shares or Other Units To Be Sold | Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Number of Shares or Other Units Outstanding financial

"Number of Shares or Other Units Outstanding"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SRPT shares did Stephen Mayo report for sale?

Stephen Mayo reported 7,239 common shares for sale, with an aggregate market value of $123,175.20 and an approximate sale date of March 12, 2026.

How did Stephen Mayo acquire the SRPT shares listed for sale?

The notice lists six restricted-stock acquisitions from Sarepta: 2,383 shares on March 10, 2026; 572 on November 16, 2022; 1,846 on March 1, 2025; 1,431 on November 16, 2024; 46 on November 16, 2023; and 961 on March 6, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001849061
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	SAREPTA THERAPEUTICS, INC.
SEC File Number	001-14895
Address of Issuer	215 First Street, Suite 415 Cambridge MASSACHUSETTS 02142
Phone	(617) 274-4000
Name of Person for Whose Account the Securities are To Be Sold	STEPHEN MAYO
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7239	123175.20	104989772	03/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/10/2026	Restricted Stock	Issuer			2383	03/10/2026	Not Applicable
Common	11/16/2022	Restricted Stock	Issuer			572	11/16/2022	Not Applicable
Common	03/01/2025	Restricted Stock	Issuer			1846	03/01/2025	Not Applicable
Common	11/16/2024	Restricted Stock	Issuer			1431	11/16/2024	Not Applicable
Common	11/16/2023	Restricted Stock	Issuer			46	11/16/2023	Not Applicable
Common	03/06/2024	Restricted Stock	Issuer			961	03/06/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	03/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Stephen Mayo
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)